中国药物经济学2024，Vol.19Issue(7)：23-30,35,9.DOI:10.12010/j.issn.1673-5846.2024.07.004
麝香保心丸与速效救心丸治疗冠状动脉粥样硬化性心脏病心绞痛的药物经济学评价
A Pharmacoeconomic Evaluation of Shexiang Baoxin Pill Versus Suxiao Jiuxin Pill in the Treatment Coronary Heart Disease
李昌 1亢泽坤 2吕维红 3胡敏 4张嵬 5刘金万6
作者信息
- 1. 石家庄市中医院药剂科,石家庄 050011
- 2. 河北医科大学第二医院药学部,石家庄 050004
- 3. 沧州市人民医院药学部,河北沧州 061002
- 4. 复旦大学公共卫生学院卫生经济学教研室,上海 200433
- 5. 复旦大学公共卫生学院医学信息和生物统计中心,上海 200433
- 6. 大连市第三人民医院药剂科,大连 116033
- 折叠
摘要
Abstract
Objective To evaluate the efficacy and economy of Shexiang Baoxin Pill and Suxiao Jiuxin Pill in treating coronary heart disease.Methods The literature published on randomized controlled trials(RCTs)of Shexiang Baoxin Pill(treatment group)and Suxiao Jiuxin Pill(control group)in the treatment of coronary heart disease were included.After screening the literature and performing the quality evaluation,RevMan 5.4 software was used for Meta-analysis,and pharmacoeconomic evaluation was performed based on the results of this analysis.Results A total of 9 literatures were included.The difference between Shexiang heart-saving pill and quick-acting heart-saving pill was 2%,95%CI(-3%～6%)in symptom response rate and 20%,95%CI(-9%～48%)in ECG response rate.Under the national average,the incremental cost-effectiveness ratio of Shexiang heart-saving pills was-211.50(improved clinical symptoms)and-40.29(improved ECG results).In most provinces and cities across the country of China,the incremental cost-effectiveness ratio of Shexiang Bao Xin Pill to improve clinical symptoms and electrocardiogram results is negative,and even in provinces and cities across the country with positive incremental cost-effectiveness ratio,the value is relatively low.Conclusion Shexiang Baoxin Pill is more effective than Suxiao Jiuxin Pill in improving symptoms and ECG results in patients with coronary angina.On average across the country,Shexiang Baoxin Pill has the absolute economic advantage over Suxiao Jiuxin Pill.关键词
麝香保心丸/速效救心丸/冠状动脉粥样硬化性心脏病/药物经济学Key words
Shexiang Baoxin Pill/Suxiao Jiuxin Pill/Coronary heart disease/Pharmacoeconomics分类
医药卫生引用本文复制引用
李昌,亢泽坤,吕维红,胡敏,张嵬,刘金万..麝香保心丸与速效救心丸治疗冠状动脉粥样硬化性心脏病心绞痛的药物经济学评价[J].中国药物经济学,2024,19(7):23-30,35,9.
